Trial · NCT05014672
Results by group59
Each measurement the trial posted, group by group, in the words and numbers it posted.
21 to 40 of 59
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Pruritus at Week 24 Compared to Baseline, as Assessed by the Worst Itch Numerical Rating Scale (WI-NRS) | Placebo | -0.56 | Standard Deviation 2.268 | units on a scale | |
| Change in Pruritus at Week 24 Compared to Baseline, as Assessed by the PBC-40 Itch Domain | Setanaxib 1200 mg/Day | -1.11 | Standard Deviation 2.111 | units on a scale | |
| Change in Pruritus at Week 24 Compared to Baseline, as Assessed by the PBC-40 Itch Domain | Setanaxib 1600 mg/Day | 0.32 | Standard Deviation 2.647 | units on a scale | |
| Change in Pruritus at Week 24 Compared to Baseline, as Assessed by the PBC-40 Itch Domain | Placebo | -0.70 | Standard Deviation 3.114 | units on a scale | |
| Change in Pruritus at Week 24 Compared to Baseline, as Assessed by the PGIS Pruritus | Setanaxib 1200 mg/Day | -0.50 | Standard Deviation 0.941 | units on a scale | |
| Change in Pruritus at Week 24 Compared to Baseline, as Assessed by the PGIS Pruritus | Setanaxib 1600 mg/Day | 0.25 | Standard Deviation 0.775 | units on a scale | |
| Change in Pruritus at Week 24 Compared to Baseline, as Assessed by the PGIS Pruritus | Placebo | -0.11 | Standard Deviation 0.758 | units on a scale | |
| Change in Pruritus at Week 24 Compared to Baseline, as Assessed by the PGIC Pruritus | Setanaxib 1200 mg/Day | 2.73 | Standard Deviation 1.751 | units on a scale | |
| Change in Pruritus at Week 24 Compared to Baseline, as Assessed by the PGIC Pruritus | Setanaxib 1600 mg/Day | 3.38 | Standard Deviation 1.244 | units on a scale | |
| Change in Pruritus at Week 24 Compared to Baseline, as Assessed by the PGIC Pruritus | Placebo | 3.37 | Standard Deviation 1.535 | units on a scale | |
| Changes in Markers of Cholestasis at Week 24 | Setanaxib 1200 mg/Day | ALP <1.67×ULN and Total Bilirubin ≤1×ULN and ≥15% ALP Reduction from Baseline | 1 | participants | |
| Changes in Markers of Cholestasis at Week 24 | Setanaxib 1600 mg/Day | ALP <1.67×ULN and Total Bilirubin ≤1×ULN and ≥15% ALP Reduction from Baseline | 4 | participants | |
| Changes in Markers of Cholestasis at Week 24 | Placebo | ALP <1.67×ULN and Total Bilirubin ≤1×ULN and ≥15% ALP Reduction from Baseline | 1 | participants | |
| Changes in Markers of Cholestasis at Week 24 | Setanaxib 1200 mg/Day | ALP <1.67×ULN and Total Bilirubin ≤1×ULN and ≥30% ALP Reduction from Baseline | 1 | participants | |
| Changes in Markers of Cholestasis at Week 24 | Setanaxib 1600 mg/Day | ALP <1.67×ULN and Total Bilirubin ≤1×ULN and ≥30% ALP Reduction from Baseline | 2 | participants | |
| Changes in Markers of Cholestasis at Week 24 | Placebo | ALP <1.67×ULN and Total Bilirubin ≤1×ULN and ≥30% ALP Reduction from Baseline | 0 | participants | |
| Changes in Markers of Cholestasis at Week 24 | Setanaxib 1200 mg/Day | ALP <1.67×ULN and Total Bilirubin ≤1×ULN and ≥40% ALP Reduction from Baseline | 0 | participants | |
| Changes in Markers of Cholestasis at Week 24 | Setanaxib 1600 mg/Day | ALP <1.67×ULN and Total Bilirubin ≤1×ULN and ≥40% ALP Reduction from Baseline | 2 | participants | |
| Changes in Markers of Cholestasis at Week 24 | Placebo | ALP <1.67×ULN and Total Bilirubin ≤1×ULN and ≥40% ALP Reduction from Baseline | 0 | participants | |
| Changes in Markers of Cholestasis at Week 24 | Setanaxib 1200 mg/Day | ALP <1.67×ULN and Total Bilirubin ≤1×ULN and ≥70% ALP Reduction from Baseline | 0 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05014672/results?page=2